Bisphosphonates: 50 years in clinical practice
- Authors: Golounina O.O.1, Belaia Z.E.2
-
Affiliations:
- Sechenov First Moscow State Medical University (Sechenov University)
- Endocrinology Research Centre
- Issue: Vol 22, No 4 (2020)
- Pages: 66-73
- Section: Articles
- URL: https://bakhtiniada.ru/2075-1753/article/view/95274
- DOI: https://doi.org/10.26442/20751753.2020.4.200102
- ID: 95274
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Olga O. Golounina
Sechenov First Moscow State Medical University (Sechenov University)
Email: olga.golounina@mail.ru
студентка 3-го курса Института клинической медицины Moscow, Russia
Zhanna E. Belaia
Endocrinology Research Centreд-р мед. наук, проф., зав. отд-нием нейроэндокринологии и остеопатий Moscow, Russia
References
- Russell RGG. Bisphosphonates: the first 40 years. Bone 2011; 49 (1): 2-19. doi: 10.1016/j.bone.2011.04.022
- Smith R, Russell RG, Bishop M. Diphosphonates and Page’s disease of bone. Lancet 1971;(7706): 945-7. doi: 10.1016/s0140-6736(71)91447-4
- Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008; 83 (9): 1032-45. doi: 10.4065/83.9.1032
- Menschutkin N. Ueber die Einwirkung des Chloracetyls auf phosphorige Saure. Ann Chem Pharm 1865; 133 (3): 317-20. doi: 10.1002/jlac.18651330307
- Fleisch H, Russell RG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969; 165 (3899): 1262-4. doi: 10.1126/science.165.3899.1262
- Russell RGG, Bisaz S, Donath A et al. Inorganic pyrophosphate in plasma in normal persons and in patients with hypophosphatasia, osteogenesis imperfecta, and other disorders of bone. J Clin Invest 1971; 50 (5): 961-9. doi: 10.1172/JCI106589
- Russell RG, Croucher PI, Rogers MJ. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 1999; 9 (Suppl. 2): 66-80. doi: 10.1007/pl00004164
- Rogers MJ, Crockett JC, Coxon FP et al. Biochemical and molecular mechanisms of action of bisphosphonates. Bone 2011; 49 (1): 34-41. doi: 10.1016/j.bone.2010.11.008
- Roelofs AJ, Thompson K, Gordon S et al. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006; 12 (20 Pt 2): 6222-30. doi: 10.1158/1078-0432.CCR-06-0843
- Lehenkari PP, Kellinsalmi M, Napankangas JP et al. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-contai-ning metabolite. Mol Pharmacol 2002; 61 (5): 1255-62. doi: 10.1124/mol.61.5.1255
- Russell RGG, Watts NB, Ebetino FH et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19 (6): 73359. doi: 10.1007/s00198-007-0540-8
- Thompson K, Rogers MJ, Coxon FP et al. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol 2006; 69 (5): 1624-32. doi: 10.1124/mol.105.020776
- Idris AI, Rojas J, Greig IR et al. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int 2008; 82 (3): 191-201. doi: 10.1007/s00223-008-9104-y
- Gong L, Altman RB, Klein TE. Bisphosphonates pathway. Pharmacogenet Genomics 2011; 21 (1): 50-3. doi: 10.1097/FPC.0b013e328335729c
- Белая Ж.Е., Рожинская Л.Я. Витамин D в терапии остеопороза: его роль в комбинации с препаратами для лечения остеопороза, внескелетные эффекты. Эффективная фармакотерапия. 2013; 38: 14-29.
- Ершова О.Б. Применение алендроната в терапии остеопороза. Ревматология. 2019; (21): 142-6. doi: 10.21518/2079-701X-2019-21-142-146
- Pols HA, Felsenberg D, Hanley DA et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999; 9 (5): 461-8. doi: 10.1007/pl00004171
- Black DM, Thompson DE, Bauer DC et al. Fracture Intervention Trial Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000; 85 (11): 4118-24. doi: 10.1210/jcem.85.11.6953
- Black DM, Schwartz AV, Ensrud KE et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296 (24): 2927-38. doi: 10.1001/jama.296.24.2927
- Wang Y-K, Zhang Y-M, Qin S-Q et al. Effects of alendronate for treatment of glucocorticoid-induced osteoporosis: A meta-analysis of randomized controlled trials. Medicine (Baltimore) 2018; 97 (42): e12691. doi: 10.1097/MD.0000000000012691
- Белая Ж.Е., Рожинская Л.Я., Колесникова Г.С. и др. Опыт применения профилактической дозы алендроната (Фосамакс 35 мг) для лечения остеопороза у женщин в постменопаузе с субклиническим тиреотоксикозом. Остеопороз и остеопатии. 2007; 1: 12-9.
- Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282 (14): 1344-52. doi: 10.1001/jama.282.14.1344
- Reginster J, Minne HW, Sorensen OH et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11 (1): 83-91. doi: 10.1007/s001980050010
- Chesnut CH, Skag A, Christiansen C et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19 (8): 1241-9. doi: 10.1359/JBMR.040325
- Epstein S, Jeglitsch M, McCloskey E. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg. Curr Med Res Opin 2009; 25 (12): 2951-60. doi: 10.1185/03007990903361307
- Белая Ж.Е., Рожинская Л.Я., Мельниченко Г.А. Ибандронат (Бонвива) - новые возможности в лечении остеопороза: повышение приверженности к терапии - оптимизация исходов лечения. Остеопороз и остеопатии. 2006; 9 (3): 23-30.
- Белая Ж.Е., Рожинская Л.Я. Рациональный выбор фармакотерапии постменопаузального остеопороза. Эффективность и безопасность Бонвивы: обзор за восемь лет применения. Остеопороз и остеопатии. 2013; 2:22-8.
- Cranney A, Wells GA, Yetisir E et al. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int 2009; 20 (2): 291-7. doi: 10.1007/s00198-008-0653-8
- Воротникова С.Ю., Пигарова Е.А. Золедроновая кислота в лечении остеопороза и других заболеваний скелета. Остеопороз и остеопатии. 2016; 3: 23-7.
- Geusens PPMM, Lems WF. Fracture prevention in postmenopausal women with osteoporosis by an annual infusion of zoledronic acid. Ned Tijdschr Geneeskd 2007; 151 (26): 1445-8.
- McClung M, Miller P, Recknor C et al. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol 2009; 114 (5): 999-1007. doi: 10.1097/AOG.0b013e3181bdce0a
- Reid IR, Horne AM, Mihov B et al. Fracture Prevention with Zoledronate in Older Women with Osteopenia. N Engl J Med 2018; 379 (25): 2407-16. doi: 10.1056/NEJMoa1808082
- Рожинская Л.Я. Болезнь Педжета. Остеопороз и остеопатии. 2007; 2: 29-31.
- Корсакова Ю.Л. Болезнь Педжета: современные методы лечения. Современная ревматология. 2010; 2: 11-7.
- Sharma A, Sinha RJ, Garg G et al. Special emphasis on bone health management in prostate cancer patients: a prospective longitudinal study. Int Braz J Urol 2020; 46 (3): 363-73. doi: 10.1590/S1677-5538.IBJU.2019.0023
- Jeon H-L, Oh I-S, Baek Y-H et al. Zoledronic acid and skeletal-related events in patients with bone metastatic cancer or multiple myeloma. J Bone Miner Metab 2020; 38 (2): 254-63. doi: 10.1007/s00774-019-01052-6
- Кулиева И.Э., Бесова Н.С. Опыт применения золедроновой кислоты (препарата Резорба) для лечения больных с костными метастазами. Эффективная фармакотерапия. 2012; 37 (2): 24-31.
- Sierra M, Alvarado M. Ramirez M et al. Hypercalcemia of Malignancy in a Patient with Hypoparathyroidism: A Complicated but Treatable Condition. P R Health Sci J 2019; 38 (4): 275-7.
- Recine F, Bongiovanni A, Foca F et al. BOne HEalth ManagEment in Patients with Early Breast Cancer: A Retrospective Italian Osteoncology Center “Real-Life” Experience (BOHEME Study). J Clin Med 2019; 8 (11). doi: 10.3390/jcm8111894
- Eguia A, Bagan-Debon L, Cardona F Review and update on drugs related to the development of osteonecrosis of the jaw. Med Oral 2020: 71-83. doi: 10.4317/medoral.23191
- Jung S-M, Han S, Kwon H-Y Dose-Intensity of Bisphosphonates and the Risk of Osteonecrosis of the Jaw in Osteoporosis Patients. Front Pharmacol 2018; 9: 796. doi: 10.3389/fphar.2018.00796
- Meyyur Aravamudan V, Er C. Osteonecrosis of the Jaw and Concomitant Atypical Femoral Fractures with Bisphosphonates: A Comprehensive Literature Review. Cureus 2019; 11 (7): e5113. doi: 10.7759/cureus.5113
- Chan BH, Yee R, Puvanendran R et al. Medication-related osteonecrosis of the jaw in osteoporotic patients: prevention and management. Singapore Med J 2018; 59 (2): 70-5. doi: 10.11622/smedj.2018014
- Odvina CV, Zerwekh JE, Rao DS et al. Severely Suppressed Bone Turnover: A Potential Complication of Alendronate Therapy. J Clin Endocrinol Metab 2005; 90 (3): 1294-301. doi: 10.1210/jc.2004-0952
- Rizzoli R, Akesson K, Bouxsein M et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 2011; 22 (2): 373-90. doi: 10.1007/s00198-010-1453-5
- Lloyd AA, Gludovatz B, Riedel C et al. Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance. Proc Natl Acad Sci USA 2017; 114 (33): 8722-7. doi: 10.1073/pnas.1704460114
- Зоткина К.Е., Лесняк О.М., Кочиш А.Ю. и др. Атипичный перелом бедренной кости на фоне лечения бисфосфонатами пациентки с постменопаузальным остеопорозом. Остеопороз и остеопатии. 2019; 22 (1): 18-23. doi: 10.14341/osteo10286
- Starr J, Tay YKD, Shane E. Current Understanding of Epidemiology, Pathophysiology, and Management of Atypical Femur Fractures. Curr Osteoporos Rep 2018; 16 (4): 519-29. doi: 10.1007/s11914-018-0464-6
- Brock GR, Chen JT, Ingraffea AR et al. The Effect of Osteoporosis Treatments on Fatigue Properties of Cortical Bone Tissue. Bone Rep 2015; 2: 8-13. doi: 10.1016/j.bonr.2014.10.004
- Khow KSF, Shibu P, Yu SCY et al. Epidemiology and Postoperative Outcomes of Atypical Femoral Fractures in Older Adults: A Systematic Review. J Nutr Health Aging 2017; 21 (1): 83-91. doi: 10.1007/s12603-015-0652-3
- Dell RM, Adams AL, Greene DF et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 2012; 27 (12): 2544-50. doi: 10.1002/jbmr.1719
- Kharazmi M, Hallberg P, Schilcher J et al. Mortality After Atypical Femoral Fractures: A Cohort Study: MORTALITY AFTER ATYPICAL FEMORAL FRACTURES. J Bone Miner Res 2016; 31 (3): 491-7. doi: 10.1002/jbmr.2767
- Dennison EM, Cooper C, Kanis JA et al. Fracture risk following intermission of osteoporosis therapy. Osteoporos Int 2019; 30 (9): 1733-43. doi: 10.1007/s00198-019-05002-w
- Bone HG, Hosking D, Devogelaer J-P et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350 (12): 1189-99. doi: 10.1056/NEJ-Moa030897
- Black DM, Reid IR, Boonen S et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012; 27 (2): 243-54. doi: 10.1002/jbmr.1494
- Curtis J, Chen R, Li Z et al. The impact of bisphosphonate drug holidays on fracture rates. Abstract 1006 presented at the ASBMR meeting 2018.
- Голоунина О.О., Белая Ж.Е., Мельниченко Г.А. Маркеры костного ремоделирования в клинической практике. Клиническая медицина. 2018; 96 (10): 876-84. doi: 10.34651/0023-21492018-96-10-876-884
- Lyles KW, Coldn-Emeric CS, Magaziner JS et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357 (18): 1799-809. doi: 10.1056/NEJMoa074941
- Cummings SR, Lui L-Y, Eastell R et al. Association Between Drug Treatments for Patients With Osteoporosis and Overall Mortality Rates: A Meta-analysis. JAMA Intern Med 2019. doi: 10.1001/ja-mainternmed.2019.2779
- Bliuc D, Tran T, van Geel T et al. Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study. Osteoporos Int 2019; 30 (4): 817-28. doi: 10.1007/s00198-018-4806-0 ИНФОРМАЦИЯ ОБ АВТОРАХ / INFORMATION ABOUT THE AUTHORS
- Lee P, Ng C, Slattery A et al. Preadmission Bisphosphonate and Mortality in Critically Ill Patients. J Clin Endocrinol Metab 2016; 101 (5): 1945-53. doi: 10.1210/jc.2015-3467
- Bergman J, Nordstrom A, Hommel A et al. Bisphosphonates and mortality: confounding in observational studies? Osteoporos Int 2019; 30 (10): 1973-82. doi: 10.1007/s00198-019-05097-1
- Скрипникова И.А., Рожинская Л.Я. Применение дженериков - способ повышения приверженности лечению остеопороза. Остеопороз и остеопатии.2010;13 (3): 36-40.
- Lai PSM, Chua SS, Chong YH et al. The effect of mandatory generic substitution on the safety of alendronate and patients’ adherence. Curr Med Res Opin 2012; 28 (8): 1347-55. doi: 10.1185/03007995.2012.708326
- Белая Ж.Е., Рожинская Л.Я. Дженерики в терапии постменопаузального остеопороза. РМЖ. 2010; 23: 14-9.
- Unnanuntana A, Jarusriwanna A, Songcharoen P Randomized clinical trial comparing efficacy and safety of brand versus generic alendronate (Bonmax*) for osteoporosis treatment. PLoS ONE 2017; 12(7): e0180325. doi: 10.1371/journal.pone.0180325
- Древаль А.В., Марченкова Л.А., Бахарева И.В. и др. Анализ клинического опыта применения отечественного дженерика золедроновой кислоты для лечения остеопороза. Лечащий врач. 2014; 5: 124.
Supplementary files
